The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | The impact of frontline maintenance therapy on myeloma patients in the UK
Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses the efficacy of lenalidomide maintenance therapy in patients with multiple myeloma. Prof. Jackson first highlights the recent approval of frontline maintenance therapy in the UK, which is extremely beneficial to patients. Maintenance therapy with lenalidomide is known to prolong progression-free survival (PFS) in patients who are measurable residual disease (MRD) positive and negative, as well as those with high-risk cytogenetics. Prof. Jackson also explains how data from the Myeloma XI trial (NCT01554852) and the STaMINA trial (NCT02322320) support the continued use of lenalidomide maintenance in myeloma treatment. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Speaker honoraria engagements: Amgen, Takeda, Johnson & Johnson, Sanofi, Celgene and Roche; Research funding: Takeda, Onyx and Celgene; Advisory Boards: Amgen, Takeda, Johnson & Johnson, Oncopeptides, Pfizer, Sanofi, Celgene, GSK and Roche; Board of directors Myeloma UK.
